aTyr Pharma Announces First Quarter 2021 Results and Provides Corporate Update
aTyr Pharma, Inc. (LIFE)
Last atyr pharma, inc. earnings: 3/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
atyrpharma.com/investors-media
Company Research
Source: GlobeNewswire
Data from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis expected in the third quarter. Preclinical data for IND candidate ATYR2810 showed anti-tumor effects in models of TNBC and NSCLC. Bispecific antibody project with subsidiary Pangu BioPharma achieved milestones for first of two-year project. Ended the quarter with $50.6 million in cash, cash equivalents and investments. Company to host conference call and webcast today, May 13, at 5:00 p.m. EDT / 2:00 p.m. PDT. SAN DIEGO, May 13, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced first quarter 2021 results and provided a corporate update. “During the first quarter, we remained focused on advancing our lead therapeutic candidate, ATYR1923. We are tracking towards the readout from our Phase 1b/2a proof-of-concept study in pulmonary sarcoidosis, o
Show less
Read more
Impact Snapshot
Event Time:
LIFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LIFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LIFE alerts
High impacting aTyr Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
LIFE
News
- aTyr Pharma Insiders Placed Bullish Bets Worth US$514.6k [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma to Participate in April Investor ConferencesGlobeNewswire
- aTyr Pharma, Inc. (NASDAQ: LIFE) had its price target lowered by analysts at Royal Bank of Canada from $19.00 to $16.00. They now have an "outperform" rating on the stock.MarketBeat
- aTyr Pharma Full Year 2023 Earnings: Revenues Disappoint [Yahoo! Finance]Yahoo! Finance
- aTyr Pharma, Inc. (NASDAQ:LIFE) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
LIFE
Earnings
- 3/14/24 - Miss
LIFE
Sec Filings
- 4/5/24 - Form ARS
- 4/5/24 - Form DEFA14A
- 4/5/24 - Form DEF
- LIFE's page on the SEC website